Patents Assigned to Pharmacia Corporation
  • Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
    Patent number: 6852761
    Abstract: The invention relates to polycyclic aryl and heteroaryl substituted benzene compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: March 13, 2001
    Date of Patent: February 8, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, John J. Parlow
  • Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
    Patent number: 6849653
    Abstract: The present invention relates to substituted pyrazolyl derivatives, compositions comprising such, intermediates, methods of making substituted pyrazolyl derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: February 1, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael Clare, Lifeng Geng, Gunnar J. Hanson, He Huang, Donna M. Iula, Shuyuan Liao, Michael A. Stealey, Richard M. Weier, Suzanne Metz, Michael L. Vazquez
  • Combination of an aldosterone receptor antagonist and an anti-diabetic agent
    Publication number: 20050014732
    Abstract: A combination therapy comprising a therapeutically-effective amount of an aldosterone receptor antagonist and a therapeutically-effective amount of an anti-diabetic agent is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred antidiabetic agents are those compounds having high potency and oral or parenteral bioavailability. Preferred aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9?,11?-substituted epoxy moiety.
    Type: Application
    Filed: January 30, 2004
    Publication date: January 20, 2005
    Applicant: Pharmacia Corporation
    Inventors: Eric Gulve, Ellen McMahon
  • Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
    Publication number: 20050014729
    Abstract: A method for preventing or treating dermatological disorders and dermatological disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a dermatological treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a dermatological treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.
    Type: Application
    Filed: June 3, 2004
    Publication date: January 20, 2005
    Applicant: Pharmacia Corporation
    Inventor: Steven Pulaski
  • Retroviral protease inhibitors
    Publication number: 20050004230
    Abstract: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Type: Application
    Filed: March 5, 2004
    Publication date: January 6, 2005
    Applicant: Monsanto Company (now named Pharmacia Corporation, which is a wholly owned subsidiary of Pfizer, Inc
    Inventors: John Talley, Daniel Getman, Gary DeCrescenzo, Kathryn Reed, Ko-Chung Lin, John Freskos, Michael Clare, Donald Rogier, Robert Heintz, Michael Vazquez, Richard Mueller
  • Treatment of Alzheimer's disease with the R(-) isomer of a 2-arylpropionic acid non-steroidal anti-inflammatory drug alone or in combination with a cyclooxygenase-2 selective inhibitor
    Publication number: 20050004224
    Abstract: A method for preventing, treating or ameliorating Alzheimer's disease in a subject that is in need of such prevention, treatment or amelioration, comprises administering to the subject a compound containing an R(?) isomer of a 2-arylpropionic acid non-steroidal anti-inflammatory drug, alone or in combination with a cyclooxygenase-2 selective inhibitor. Compositions, pharmaceutical compositions, and kits which are useful in practicing the method are also disclosed.
    Type: Application
    Filed: June 7, 2004
    Publication date: January 6, 2005
    Applicant: Pharmacia Corporation
    Inventor: Philip Needleman
  • Combination of an aldosterone receptor antagonist and a renin inhibitor
    Publication number: 20040266743
    Abstract: Novel combinations, compositions, and therapeutic methods of treatment of a hypertension, cardiovascular disease, renal dysfunction, edema, cerebrovascular disease, or insulinopathy pathological condition in a subject, wherein the methods comprise the administration of a combination of one or more aldosterone receptor antagonists and one or more renin inhibitors.
    Type: Application
    Filed: April 29, 2004
    Publication date: December 30, 2004
    Applicant: Pharmacia Corporation
    Inventors: Ellen G. McMahon, Amy E. Rudolph
  • Fluorescent methods for the high-throughput quantification of tartrate-resistant acid phosphatase (TRAP)
    Publication number: 20040259184
    Abstract: Methods for quantifying tartrate-resistant acid phosphotase (TRAP) activity, or determining the distribution of TRAP in a tissue are provided. More specifically, the fluorescent assay of the present invention is useful for identifying or quantifying TRAP in isolated osteoclast cells or osteoclasts differentiated from RAW264.7 monocyte-macrophage cells.
    Type: Application
    Filed: May 7, 2004
    Publication date: December 23, 2004
    Applicant: Pharmacia Corporation
    Inventors: Lee Albee, Gabriel Mbalaviele
  • Dihydrostilbene alkanoic acid derivatives
    Patent number: 6833366
    Abstract: The present invention relates to a class of compounds represented by the Formula 1. or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula 1, and methods of selectively inhibiting or antagonizing the &agr;v&bgr;3 and/or the &agr;v&bgr;5 integrin.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: December 21, 2004
    Assignee: Pharmacia Corporation
    Inventors: Thomas Rogers, Michael Clare, Hwang-Fun Lu, Mark Russell, James W. Malecha, Ish Kumar Khanna, Thomas Penning, Srinivasan Raj Nagarajan
  • Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
    Publication number: 20040248943
    Abstract: This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.
    Type: Application
    Filed: July 8, 2002
    Publication date: December 9, 2004
    Applicant: Pharmacia Corporation
    Inventors: John J. Talley, James A. Sikorski, Matthew J. Graneto, Bryan H. Norman, Balekudru Devadas, Hwang-Fun Lu
  • Aromatic thioether liver X-receptor modulators
    Patent number: 6828446
    Abstract: The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: December 7, 2004
    Assignee: Pharmacia Corporation
    Inventors: Nizal S. Chandrakumar, Christopher R. Dalton, James W. Malecha, Michael B. Tollefson, Jennifer Ann Van Camp, Phillip B. Cox
  • Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
    Patent number: 6828338
    Abstract: The present invention relates to compounds, and prodrugs thereof, composition and methods useful for preventing and treating thrombotic conditions in mammals. The compounds of the present invention, and prodrugs thereof, selectively inhibit certain proteases of the coagulation cascade.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: December 7, 2004
    Assignee: Pharmacia Corporation
    Inventors: Michael J. South, Brenda Case, Danny J. Garland, Michael J. Hayes, Horng-Chih Huang, Wei Huang, Darin E. Jones, William L. Neumann, John J. Parlow, David B. Reitz, Melvin L. Rueppel, Rondald K. Webber
  • 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
    Patent number: 6828456
    Abstract: The present invention relates to 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.
    Type: Grant
    Filed: September 15, 2001
    Date of Patent: December 7, 2004
    Assignee: Pharmacia Corporation
    Inventors: Donald W. Hansen, Jr., Ronald Keith Webber
  • Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
    Publication number: 20040235925
    Abstract: A method of treating, preventing, or inhibiting a CNS disorder and/or pain and inflammation or an inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of duloxetine, venlafaxine or atomoxetine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a CNS disorder, pain and inflammation, or inflammation-associated disorder suppressing treatment, prevention, or inhibition effective amount of the composition. Compositions and pharmaceutical compositions that contain duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor are also disclosed.
    Type: Application
    Filed: December 4, 2003
    Publication date: November 25, 2004
    Applicant: Pharmacia Corporation
    Inventor: Stephen P. Arneric
  • Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2 mediated disorders
    Patent number: 6822102
    Abstract: A class of dihydrobenzopyrans, dihydrobenzothiopyrans, tetrahydroquinolines, tetrahydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: November 23, 2004
    Assignee: Pharmacia Corporation
    Inventors: Donald Rogier, Jr., Jeffery Carter, John Talley
  • Sulfone liver X-receptor modulators
    Patent number: 6822120
    Abstract: The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: November 23, 2004
    Assignee: Pharmacia Corporation
    Inventors: Daniel P. Becker, Gary A. DeCrescenzo, James W. Malecha, Julie M. Miyashiro, Jennifer Ann Van Camp, Joe T. Collins
  • Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
    Publication number: 20040229803
    Abstract: The present invention provides compositions and methods for the treatment of pain, inflammation or inflammation mediated disorders in a subject. More particularly, the invention provides a combination therapy for the treatment of pain, inflammation or inflammation mediated disorders comprising the administration to a subject of a potassium ion channel modulator in combination with a cyclooxygenase-2 selective inhibitor.
    Type: Application
    Filed: April 21, 2004
    Publication date: November 18, 2004
    Applicant: Pharmacia Corporation
    Inventors: Diane T. Stephenson, Duncan P. Taylor
  • Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
    Publication number: 20040224940
    Abstract: The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a sodium ion channel blocker in combination with a cyclooxygenase-2 selective inhibitor.
    Type: Application
    Filed: April 21, 2004
    Publication date: November 11, 2004
    Applicant: Pharmacia Corporation
    Inventors: Diane T. Stephenson, Duncan P. Taylor
  • Methods for treating glaucoma
    Patent number: 6814966
    Abstract: This invention provides a method for treating a subject with glaucoma comprising the steps of administrating a compound or composition which antagonize, inhibits, inactivates, reduce, suppresses, antagonizes, and/or limits the release, synthesis, or production from cells of TNF-&agr; thereby treating the subject with glaucoma.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: November 9, 2004
    Assignee: Pharmacia Corporation
    Inventors: Martin B. Wax, Gulgun Tezel
  • Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
    Patent number: 6815460
    Abstract: Prodrugs of COX-2 inhibitors and methods of their preparation are described. The prodrugs of COX-2 inhibitors are described as being useful in treating inflammation and inflammation-related disorders.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: November 9, 2004
    Assignee: Pharmacia Corporation
    Inventors: John J Talley, James W Malecha, Stephen Bertenshaw, Matthew J Graneto, Jeffery Carter, Jinglin Li, Srinivasan Nagarajan, David L Brown, Donald J Rogier, Jr., Thomas D Penning, Ish K Khanna, Xiangdong Xu, Richard M Weier